Prostate Cancer: Drug Combo Lowers Death Risk by 40% in Aggressive Cases

Men with prostate cancer that returns after surgery or radiation and are left with few options could benefit from a new ...

FDA unveils drugs to receive expedited review in support of 'national priorities'

The Food and Drug Administration is announcing the first round of drugs that will receive drastically expedited reviews at ...

US FDA expands use of Amgen, AstraZeneca's drug for chronic inflammatory sinus disease

The U.S. Food and Drug Administration has approved Amgen and AstraZeneca's drug for a type of chronic inflammatory sinus ...

US FDA announces recipients of national priority vouchers

The U.S. Food and Drug Administration on Thursday announced the names of nine products, under a new fast-track review process ...

Trump moves to lower IVF costs with insurance guidance, drug agreement

President Trump announced a pair of efforts Thursday aimed at expanding access to in vitro fertilization (IVF) as he seeks to ...

‘Dancing patients’ aren’t the biggest problem with drug ads

Improving drug ads by requiring them to present benefit and harm data can be a powerful tool for adding needed transparency ...

FDA awards 9 companies a new ‘national priority’ voucher to speed drug reviews

A gene therapy from Regeneron, a pancreatic cancer medicine from Revolution Medicines and a porphyria drug from Disc Medicine ...
STAT

FDA announces first nine recipients of priority drug review vouchers

FDA announced the first nine recipients of priority review vouchers, which offers expedited drug review to products aligned ...

White House announces IVF drug pricing deal for ‘TrumpRx’ site

EMD Serono will sell fertility drugs on the Trump direct-to-consumer marketplace. Trump also preview plans to encourage ...

USDA and FDA food recalls are on the rise. What happens to the waste?

The Food and Drug Administration recalled nearly 85 million units through the first half of the year and managing this ...
STAT

Biotech leaders say uncertainty at FDA threatens drug development

The FDA's rejections of Replimune and Capricor therapies show how instability threatens biotech innovation, CEOs say.
Science Daily

This powerful drug combo cuts prostate cancer deaths by 40%

A new drug combo of enzalutamide and hormone therapy has been shown to extend survival for men with recurring prostate cancer, reducing death risk by over 40%. The study followed more than 1,000 ...